Novo Nordisk's raised forecast fails to change the debate over its obesity business
· cnbc.com
Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
Novo Nordisk's quarterly beat and guidance increase did little to resolve Wall Street's biggest concern: whether the Ozempic maker has a convincing path back to...